导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.27% | 2776/4773 |
| 近一周 | -0.01% | 852/5465 |
| 近一月 | -2.63% | 1796/5421 |
| 近一季 | -10.79% | 3827/5231 |
| 近半年 | -7.27% | 3315/4920 |
| 近一年 | -4.51% | 3146/4394 |
| 近两年 | 115.57% | 462/2954 |
| 近三年 | 69.62% | 356/2253 |
| 成立以来 | 77.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.11% 1631/4961 |
11.82% 2288/5312 |
- - |
- - |
| 2025 | 41.74% 723/4813 |
8.63% 438/3635 |
-0.06% 2797/4076 |
43.45% 654/4524 |
-8.99% 3987/4813 |
| 2024 | 23.79% 319/3463 |
-7.84% 2197/2808 |
-1.08% 920/3014 |
14.38% 1984/3129 |
18.72% 65/3463 |
| 2023 | -4.09% 663/2656 |
9.82% 393/2280 |
0.07% 345/2385 |
-10.40% 1993/2515 |
-2.59% 497/2655 |
| 2022 | -29.05% 1585/2207 |
-24.74% 1777/1919 |
4.82% 971/2016 |
-16.26% 1432/2113 |
7.41% 313/2208 |
| 2021 | -2.35% 848/1822 |
-9.22% 1106/1255 |
15.99% 214/1330 |
-10.26% 1219/1466 |
3.35% 448/1822 |
| 2020 | 41.64% 286/1250 |
4.01% 94/1028 |
25.40% 157/1067 |
4.40% 956/1164 |
4.02% 878/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 安信深圳科技指数(LOF)C VS. 长安沪深300非周期A(740101) |